The significant EPS miss and declining profitability signal weakening standalone performance, but the pending Boston Scientific acquisition provides a floor. Traders should watch for any regulatory updates on the merger and consider the stock is more tied to deal completion than fundamentals near-term.
Price Chart
Executive Summary
Penumbra Q1 2026 earnings miss: diluted EPS of $0.82 missed consensus of $1.11 by 26%, and net income declined 17% YoY to $32.6M, despite revenue growing 15.6% to $374.8M. The company withdrew guidance due to the pending Boston Scientific acquisition, but the standalone operational weakness is notable.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $374.8M, up 15.6% YoY
- Diluted EPS $0.82 vs consensus $1.11 (miss of 26%)
- Net income $32.6M, down 17% YoY from $39.2M
- Operating income $38.2M vs $40.4M in prior year
- Gross margin improved to 67.6% from 66.6% in Q1 2025
- No FY2026 guidance provided due to pending BSX acquisition
- Acquisition-related expenses of $9.4M included in SG&A
Financial Impact
EPS miss of $0.29 (26%) against consensus; operating and net income declined YoY despite revenue growth.
Risk Factors
- Acquisition failure or delay could expose stock to full operational downside
- Further earnings deterioration if acquisition closes later than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001321732-26-000018 |
| Document: pen-20260506.htm | 0001321732-26-000018 |
| Document: 0001321732-26-000018-index-headers.html | 0001321732-26-000018 |
| Document: 0001321732-26-000018-index.html | 0001321732-26-000018 |
| Document: 0001321732-26-000018.txt | 0001321732-26-000018 |
| 8-K Data (Synthetic) | 0001321732-26-000018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 30, 2026 9w ago | Press Release | $321.19 $321.68 | ▼ −0.15% | ▲ +2.84% | $317.80 (+1.05%) |
May 7, 2026 21w ago | 425 | $324.65 $319.37 | ▼ −1.63% | ▼ −4.76% | $317.80 (−2.11%) |
May 6, 2026 21w ago | 8-K | $324.65 $319.37 | ▲ +1.63% | ▲ +4.76% | $317.80 (+2.11%) |
Apr 29, 2026 22w ago | DEFA14A | $326.48 $318.30 | ▼ −2.51% | ▼ −7.73% | $317.80 (−2.66%) |
Apr 17, 2026 23w ago | 425 | $329.71 $326.54 | ▼ −0.96% | ▼ −5.16% | $317.80 (−3.61%) |
Apr 1, 2026 26w ago | DEFM14A | $330.36 $326.48 | ▼ −1.17% | ▼ −11.05% | $317.80 (−3.80%) |
Feb 25, 2026 31w ago | 8-K | $338.67 $336.27 | ▼ −0.71% | ▲ +4.53% | $317.80 (−6.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access